Home
>
US Stocks
>
Surface Oncology Inc
Surface Oncology Inc
SURF

Surface Oncology Inc (SURF)

$7.441.46%

  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open$7.32
Today Low/High$7.32 / $7.45
52 Week Low/High$4.95 / $14.4
Market Cap$332.71M

Company Details

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface's novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
OrganisationSurface Oncology Inc
HeadquatersCambridge, Massachusetts, US
Employees51
IndustryHealth Technology
CEOJ. Jeffrey Goater

Discover more

Frequently Asked Questions

What is Surface Oncology Inc (SURF) share price today?

Can Indians buy Surface Oncology Inc (SURF) shares?

How can I buy Surface Oncology Inc (SURF) shares from India?

Can Fractional shares of Surface Oncology Inc (SURF) be purchased?

What are the documents required to start investing in Surface Oncology Inc (SURF) stocks?

We are a SEBI registered investement advisor